866-997-4948(US-Canada Toll Free)

Erbitux (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Non Small Cell Lung Cancer

No. of Pages : 26 Pages

 

GlobalDatas pharmaceuticals report, Erbitux (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020 provides Erbitux sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Non-Small Cell Lung Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

 

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Erbitux including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of the drug including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2013-2020 for Erbitux in each of the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Content


1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 NSCLC Market 4
2.2 Epidemiology 4
2.3 Etiology 6
2.3.1 Tobacco 6
2.3.2 Radon 6
2.3.3 Asbestos 6
2.3.4 Other Environmental Agents 7
2.4 GlobalData Report Guidance 8


3 NSCLC Disease: Market Characterization 9
3.1 NSCLC Disease Market 9
3.2 NSCLC Disease Market Forecasts and CAGR 9
3.3 Drivers for the NSCLC Disease Market 9
3.3.1 High Incidence 10
3.3.2 High Mortality Rate 11
3.3.3 Increased Use of Chemotherapy in Early Stages of NSCLC 11
3.3.4 Emergence of Targeted Drugs and Maintenance Therapy 11
3.3.5 Promising Pipeline Drugs 11


4 Tumor-Node-Metastases (TNM) Classification of NSCLC 12


5 Erbitux 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.4 Approval History of Erbitux 16
5.5 Factors Affecting Sales of Erbitux 16
5.5.1 NSCLC Market 16
5.5.2 Mechanism of action 16
5.5.3 High overall survival 16
5.5.4 Uncertainty with respect to its approval in EU 17
5.5.5 Approval in the US 17
5.5.6 Cost-benefit trade-off 17
5.5.7 Presence in Market Prior to NSCLC market approval 17
5.6 Drug Risk Benefit Score 17
5.6.1 Efficacy 18
5.6.2 Safety 18
5.6.3 Compliance 18
5.6.4 Dosing Convenience 18
5.7 Intensity of Competition 18
5.8 Sales forecast 19
5.8.1 Target patient Pool of Erbitux 19
5.8.2 Dosing 19
5.8.3 Market Penetration 19
5.8.4 Annual Cost of Therapy 20
5.8.5 Sales Projections of Erbitux 20


6 NSCLC Market: Appendix 22
6.1 Market Definitions 22
6.2 List of Abberiviations 22
6.3 Research Methodology 22
6.3.1 Coverage 23
6.3.2 Secondary Research 23
6.3.3 Forecasting 23
6.3.4 Number of Patients Approved to take the Drug 23
6.3.5 Net Penetration of Drug 24
6.3.6 Net Annual Dosing 25
6.3.7 Annual Cost of Therapy 25
6.3.8 Primary Research 25
6.3.9 Expert Panels 25
6.4 Contact Us 26
6.5 Disclaimer 26
6.6 Sources 26

List of Table


Table 1: NSCLC, Incidences and Mortality, 20082030 5
Table 2: NSCLC, Global, Market Size Forecast ($bn), 20092020 9
Table 3: Clinical Trial Results (first-line treatment) 16
Table 4: Approval History of Erbitux 16
Table 5: Drug Risk Benefit Score of Erbitux 18
Table 6: Annual Cost of Therapy, The US 20
Table 7: NSCLC, The US, Estimated Sales for Erbitux ($m), 20132020 20

List of Chart

 

Figure 1: Percentage Distribution of Top 20 Cancers 4

Figure 2: Difference of % Distribution of Incidence and Mortality of Top 20 Cancers 5

Figure 3: Percentage Distribution of Different Types of NSCLC according to Incidence, 2008 6

Figure 4: % Share of Risk Factors in Developed Countries 7

Figure 5: Per Capita Cigarette Consumption, The US, 1976-2006 7

Figure 6: NSCLC, Global, Market Size Forecast ($bn), 2009–2020 9

Figure 7: NSCLC, Global, Incidence (in millions), 2008-2030 10

Figure 8: Oncology, Global, Incidence (in millions), 2008-2030 10

Figure 9: Broad Classification of NSCLC 12

Figure 10: Detailed TNM Classification 13

Figure 11: Classification of NSCLC 14

Figure 12: Drug Model Diagram of Erbitux 19

Figure 13: NSCLC, The US, Estimated Sales for Erbitux ($m), 2013–2020 21

Figure 14: GlobalData Methodology 22

Figure 15: Drug Model Diagram 24

Figure 16: Patients Approved for the Drug 24

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *